What you carry at this position in your DNA and what research says about it.
Dopamine Receptor Activity: 5/10 evidence, 30 publications.
You're viewing every possible genotype for this variant.
None of these is your result. Use the genotype toggle to compare them, then sign up and upload your DNA to see which one is yours.
Sample genotype (not yours): A/A
Mixed Dopamine Profile with Higher Schizophrenia and Migraine Risks
This genotype is linked to an increased risk of schizophrenia and migraine headaches. However, it also offers a protective effect against developing heroin addiction and predicts a better response to headache drug withdrawal therapy.
What this genotype means: Increased risk of schizophrenia and migraine headaches; Lower susceptibility to developing heroin addiction; Poorer response to the migraine medication rizatriptan.
Sample genotype (not yours): A/G
Typical Dopamine Profile with Elevated Antipsychotic Weight Gain Risk
This genotype is associated with a typical risk for most dopamine-related conditions. However, it carries an increased likelihood of weight gain when taking antipsychotics and a poorer response to certain migraine treatments.
What this genotype means: Increased risk of weight gain when taking antipsychotic medications; Poorer clinical response to the migraine medication rizatriptan; Typically reduced response during methadone therapy.
Sample genotype (not yours): G/G
Typical Dopamine Profile with Lower Migraine Risk
This genotype is associated with a typical risk for schizophrenia and a lower susceptibility to migraine headaches. It also predicts a typical response to antipsychotic medications without an elevated risk of drug-induced weight gain.
What this genotype means: Lower susceptibility to experiencing migraine headaches; Typical baseline risk for schizophrenia and related conditions; No elevated risk of weight gain when taking antipsychotic medications.
Gene function and biological role
Gene Function: The DRD2 gene encodes the dopamine receptor D2, a key protein involved in the brain's reward, movement, and cognitive pathways. This receptor binds to dopamine, a neurotransmitter that regulates pleasure, motivation, and motor control. Variations in this gene can alter receptor density and how efficiently signals are transmitted across synapses. Consequently, DRD2 is heavily studied in relation to psychiatric conditions, substance use disorders, and response to therapeutic drugs [1]. Understanding how this gene functions helps clarify individual differences in behavior and medication outcomes [2].
Variant Impact: The rs6275 variant is a synonymous change in exon 7 of the DRD2 gene, meaning it does not alter the final amino acid sequence of the dopamine D2 receptor. Despite being a silent mutation, this genetic change can significantly influence how the gene is processed. It has been shown to affect mRNA stability, translation efficiency, and the alternative splicing of the receptor into its long and short isoforms [3]. These molecular alterations ultimately modify dopamine receptor expression levels in the brain [4]. Consequently, this variant is associated with susceptibility to neurological conditions and variations in drug response [5].
Key Insight: A silent mutation that does not change the protein sequence can still alter brain chemistry by changing how the gene is spliced and expressed.
Location: DRD2. Chromosome 11 · 11q23.2 · 113.4 Mb
Estimated prevalence by population
Global 19.1%; European 9.0%; African 39.3%; East Asian 29.0%; South Asian 14.9%; Americas 14.8%; Ashkenazi 11.7%; Finnish 11.6%; Middle Eastern 16.1%; Amish 8.4%.
Estimated AA genotype frequency.
Global 44.6%; European 42.0%; African 46.8%; East Asian 49.7%; South Asian 47.4%; Americas 47.4%; Ashkenazi 45.0%; Finnish 44.9%; Middle Eastern 48.1%; Amish 41.1%.
Estimated AG genotype frequency.
Global 36.3%; European 48.9%; African 13.9%; East Asian 21.3%; South Asian 37.8%; Americas 37.8%; Ashkenazi 43.2%; Finnish 43.5%; Middle Eastern 35.8%; Amish 50.5%.
Estimated GG genotype frequency.
Showing effects for A/A genotype
Neurology & Mental Health
Psychotic Disorders
Schizophrenia. Evidence: 4/10. Source: PMID 27254804. Increased Risk.
Addiction & Reward
Opioid Use Disorder. Evidence: 5/10. Source: PMID 19373123. Lower Risk.
Headache & Migraine
Migraine. Evidence: 4/10. Source: PMID 22875483. Increased Risk.
Rizatriptan Response. Evidence: 5/10. Source: PMID 17563839. Poorer Response.
Headache Drug Response. Evidence: 5/10. Source: PMID 25096645. Stronger Response.
Pharmacogenomics
Antidepressant & Psychiatric Drug Response
Antipsychotic Weight Gain. Evidence: 5/10. Source: PMID 27217270. Increased Risk.
Showing effects for A/G genotype
Schizophrenia. Evidence: 4/10. Source: PMID 27254804. Typical Risk.
Opioid Use Disorder. Evidence: 5/10. Source: PMID 19373123. Typical Risk.
Migraine. Evidence: 4/10. Source: PMID 22875483. Typical Risk.
Headache Drug Response. Evidence: 5/10. Source: PMID 25096645. Typical Response.
Showing effects for G/G genotype
Migraine. Evidence: 4/10. Source: PMID 22875483. Lower Risk.
Rizatriptan Response. Evidence: 5/10. Source: PMID 17563839. Typical Response.
Antipsychotic Weight Gain. Evidence: 5/10. Source: PMID 27217270. Typical Risk.
What this genotype means for the people who carry it
Sample genotype: AA (Homozygous)
Having two copies of the A allele is associated with a higher susceptibility to schizophrenia and elevated fasting blood glucose levels in affected individuals [1]. This genetic profile is also linked to an increased risk of experiencing migraine headaches [2]. When treated with certain antipsychotic medications, individuals with this genotype may have a higher likelihood of experiencing weight gain [3]. On the therapeutic front, this genotype is associated with a poorer response to the migraine drug rizatriptan [4]. Conversely, carriers of this genotype show a significantly lower rate of heroin dependence, suggesting a protective effect against opioid addiction [5]. Additionally, during drug withdrawal therapy for medication overuse headaches, this profile is linked to a decreased likelihood of experiencing withdrawal symptoms and rebound headaches [6].
Increased risk of schizophrenia and migraine headaches; Lower susceptibility to developing heroin addiction; Poorer response to the migraine medication rizatriptan; Better response to drug withdrawal therapy for medication overuse headaches.
Sample genotype: AG (Heterozygous)
Carrying one copy of the A allele and one copy of the G allele generally results in a typical baseline risk for schizophrenia and migraines. However, this genotype is associated with an increased likelihood of weight gain when treated with antipsychotic medications [1]. It is also linked to a poorer clinical response to the migraine medication rizatriptan [2]. When undergoing methadone maintenance therapy for opioid dependence, individuals with this profile typically respond less strongly to methadone [3]. Additionally, there is an increased likelihood of experiencing drowsiness when using opium alkaloids or derivatives [4]. Overall, this profile represents an intermediate state where some medication-related side effects are more prominent, while general disease risks remain close to the population average.
Increased risk of weight gain when taking antipsychotic medications; Poorer clinical response to the migraine medication rizatriptan; Typically reduced response during methadone therapy.
Sample genotype: GG (Homozygous)
Having two copies of the G allele is considered a highly favorable profile for several dopamine-related traits. This genotype is associated with a lower risk of developing migraine headaches, offering a protective effect [1]. It also represents the baseline, typical risk for schizophrenia, with ClinVar classifying the G allele as benign for this condition. Unlike carriers of the A allele, individuals with this profile do not have an elevated risk of weight gain when taking antipsychotic medications [2]. However, when using opium alkaloids or derivatives, there is an increased likelihood of experiencing drowsiness as a side effect [3]. Overall, this genetic makeup provides a stable dopaminergic baseline, avoiding the primary neurological risks and medication sensitivities associated with the minor A allele.
Lower susceptibility to experiencing migraine headaches; Typical baseline risk for schizophrenia and related conditions; No elevated risk of weight gain when taking antipsychotic medications.
Variants with shared genetic architecture
rs2514218 · DRD2 Gene · Chr 11 · Mental Health Risk
rs1801028 · DRD2 Gene · Chr 11 · Schizophrenia Risk
rs6277 · DRD2 Gene · Chr 11 · Dopamine Receptor Function
Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms.
Dopamine 2 Receptor Genes Are Associated with Raised Blood Glucose in Schizophrenia.
Association study between clinical response to rizatriptan and some candidate genes.
Content updated August 2026.
ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.
Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026
Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com